Previous studies show that uPAR, a cellular receptor, is expressed in 60%–90% of invasive breast cancer tumors; 54% of early stage ductal carcinoma in situ (DCIS) cells express a high level of uPAR [24,25]. This evidence concerns the gene PLAUR and ductal breast carcinoma in situ.